Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program

Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in NPDR and DME

Read more at globenewswire.com